miR-34a-Mediated Survivin Inhibition Improves the Antitumor Activity of Selinexor in Triple-Negative Breast Cancer

• Main Authors: Silvia Martini (Author), Valentina Zuco (Author), Monica Tortoreto (Author), Stefano Percio (Author), Elisa Campi (Author), Rihan El Bezawy (Author), Valentina Doldi (Author), Yosef Landesman (Author), Marzia Pennati (Author), Nadia Zaffaroni (Author)
• Format: Book
• Published: MDPI AG, 2021-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Triple-negative breast cancer (TNBC) is an aggressive disease with limited therapeutic options. Here, we pursued a combinatorial therapeutic approach to enhance the activity of selinexor, the first-in-class XPO1 inhibitor, by miR-34a ectopic expression in human TNBC experimental models. Anti-prolife...